IGM Biosciences Management
Management criteria checks 2/4
IGM Biosciences' CEO is Mary Harler, appointed in Oct 2024, has a tenure of less than a year. total yearly compensation is $8.87M, comprised of 6.2% salary and 93.8% bonuses, including company stock and options. directly owns 0.04% of the company’s shares, worth $29.70K. The average tenure of the management team and the board of directors is 3.8 years and 6.4 years respectively.
Key information
Mary Harler
Chief executive officer
US$8.9m
Total compensation
| CEO salary percentage | 6.17% |
| CEO tenure | less than a year |
| CEO ownership | 0.04% |
| Management average tenure | 3.8yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Feb 12
IGM Biosciences Stock: Bad News With No Turnaround In Sight
Jan 10We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Oct 08IGM Biosciences: Waiting For Godot
Sep 18IGM Biosciences: Unlikely To Move The Needle Again In 2024
May 12Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?
Apr 28IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Feb 12We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully
Nov 20We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn
May 10Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$199m |
| Dec 31 2024 | US$9m | US$547k | -US$196m |
| Sep 30 2024 | n/a | n/a | -US$220m |
| Jun 30 2024 | n/a | n/a | -US$220m |
| Mar 31 2024 | n/a | n/a | -US$237m |
| Dec 31 2023 | US$2m | US$486k | -US$246m |
Compensation vs Market: Mary's total compensation ($USD8.87M) is above average for companies of similar size in the US market ($USD647.94K).
Compensation vs Earnings: Mary's compensation has increased whilst the company is unprofitable.
CEO
Mary Harler (60 yo)
Ms. Mary Beth Harler, M.D. is the Chief Executive Officer and Director of IGM Biosciences, Inc. since October 01, 2024. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. since 2024 and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$8.87m | 0.040% $ 29.7k | |
| Chief Financial Officer | 6.4yrs | US$2.48m | 0.046% $ 34.2k | |
| Chief Business Officer | 4.3yrs | US$1.29m | 0.037% $ 27.5k | |
| Senior Vice President of Group Operations | 2.4yrs | no data | no data | |
| Senior VP | 3.3yrs | no data | 0.0070% $ 5.3k | |
| Senior Vice President of Legal Affairs | 4.4yrs | no data | no data | |
| Chief Human Resources Officer | 6yrs | no data | no data | |
| Senior Vice President of Quality | 2.4yrs | no data | no data |
Experienced Management: IGMS's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$8.87m | 0.040% $ 29.7k | |
| Independent Director | 4.4yrs | US$307.94k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$350.40k | 0.68% $ 513.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.9yrs | US$297.76k | 0.020% $ 14.9k | |
| Independent Director | 6.8yrs | US$297.76k | 0.15% $ 113.6k | |
| Independent Director | 6.8yrs | US$291.84k | 0.0033% $ 2.5k | |
| Independent Director | 6.8yrs | US$335.09k | 0.084% $ 63.4k | |
| Independent Director | 6.8yrs | US$1.54m | 0.19% $ 144.5k | |
| Independent Director | 1.7yrs | US$320.21k | 0.011% $ 8.1k | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: IGMS's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 12:01 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IGM Biosciences, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Anderson | BofA Global Research |
| Michael Schmidt | Guggenheim Securities, LLC |
| Biren Amin | Jefferies LLC |